Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Per the activity note to the FY2024 annual report, the company conducts retail and wholesale trade in medications.
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 2,012 | 2,394 | 2,009 | 3,036 | 4,025 | 7,593 | 9,032 | +28.4% |
| Total COGS | 1,739 | 2,019 | 1,721 | 2,316 | 2,933 | 5,183 | 7,137 | +26.5% |
| Gross Profit | 273 | 375 | 288 | 720 | 1,092 | 2,410 | 1,895 | +38.1% |
| Gross Margin | 13.6% | 15.7% | 14.3% | 23.7% | 27.1% | 31.7% | 21.0% | |
| 147 | 50 | 128 | 24 | 390 | 484 | 15 | nmf | |
| EBITDA | 420 | 426 | 160 | 745 | 702 | 1,926 | 1,880 | +28.4% |
| EBITDA Margin | 20.9% | 17.8% | 7.9% | 24.5% | 17.4% | 25.4% | 20.8% | |
| Total D&A | 1 | 1 | 2 | 3 | 33 | 43 | 45 | +95.1% |
| EBIT / Operating Income | 419 | 424 | 157 | 742 | 669 | 1,882 | 1,835 | +27.9% |
| Total Interest Expense | 0 | 5 | 0 | 0 | 0 | 0 | 0 | |
| 13 | 53 | 39 | 334 | 127 | 43 | 1,272 | nmf | |
| Profit Before Tax | 407 | 366 | 197 | 1,076 | 797 | 1,840 | 3,107 | +40.3% |
| Total Income Tax | 0 | 38 | 28 | 1 | 76 | 0 | 160 | +33.0% |
| Net Profit / (Loss) | 407 | 327 | 52 | 744 | 730 | 1,755 | 2,083 | +31.3% |
| Net Margin | 20.2% | 13.7% | 2.6% | 24.5% | 18.1% | 23.1% | 23.1% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →